A stitch in time saves lives in certain heart attack patients

Washington D.C. [USA], May 13 : Early treatment in the patients with a severe type of heart attack can add years to their lives, according to a recent study.

An analysis of non-ST elevation myocardial infarction (NSTEMI) patients, who undergo coronary revascularization within 24 hours of hospitalization, showed an increased reduction in mortality, marking the first time this difference has been demonstrated.

Results from the study were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.

NSTEMI is a type of heart attack that occurs when an artery is only partially blocked as opposed to a STEMI, or ST-Elevation Myocardial Infarction, where there is a complete blockage of the artery, making it the more severe of the two types.

While current guidelines recommend early intervention, defined as less than 24 hours, for STEMI patients, a delayed or late strategy, defined as between 24-72 hours, for NSTEMI is considered reasonable, unless there are extenuating circumstances, such as refractory angina or other conditions that put the patient in a higher risk category.

However, the optimum time for coronary revascularization of NSTEMI patients is under debate, according to lead investigator Sameer Arora.

Evidence for current recommendations is based on clinical trials in controlled settings and selected patients.

Arora and his collaborators looked at data from the ARIC Community Surveillance Study, a large, ongoing investigation that began in 1987 involving 21 hospitals in four states: Maryland, Minnesota, Mississippi, and North Carolina.

Arora analyzed data from hospitalized NSTEMI patients undergoing coronary revascularization, and classified them as low or high risk, based on accepted risk scores.

The survival benefit of an early revascularization (less than 24 hours after symptoms start) vs. a late revascularization was analyzed using statistical models. Arora noted, "What we observed was both low- and high-risk NSTEMI patients who were treated within 24 hours of symptom onset had a 28-day survival benefit.

To our knowledge, no clinical trials to date have reported a survival benefit related to early versus late revascularization.".

Source: ANI